Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials

Abstract

This pooled, patient-level analysis indicates that the FIREHAWK stent exhibits a promising 2-year efficacy and safety profile.

Randomized comparison of novel biodegradable polymer and durable polymer‐coated cobalt‐chromium sirolimus‐eluting stents: Three‐Year Outcomes of the I‐LOVE‐IT 2 Trial

“…Subgroup analysis showed that the BP‐SES significantly favored lesions ≤20 mm versus >20 mm in TLF (5.7% vs. 12.2%, P = 0.01), primarily driven by higher periprocedural TV‐MI, which was related to the PCI process and jeopardized side branch after PCI. Although much shorter than other long‐stent studies, such as the LONG‐DES‐V trial, the 12‐month TLFs of the DP‐BES and DP‐EES were 16.3% and 16.5%, respectively , and our finding was consistent with that of the TARGET study, with another BP‐SES (Firehawk, Microport Medical, Shanghai, China) demonstrated that longer lesion was an independent predictor for 2‐year TLF (HR 2.44, 95% CI 1.32–4.53) . One possible explanation is that BP might be less physically robust than DP when pushing DES, particularly in longer lesions.…”

Comparison between imported versus domestic drug‐eluting stents in China: A large single‐center data

“…However, it is still noteworthy that in this study, in domestic DES group, the proportion of patients involved first generation DES implantation was significantly higher than that in imported DES group (32.4% vs 3.8%, P < 0.001), and second generation and biodegradable polymer DESs had been confirmed to be superior to first generation DES . In addition, newest domestic DES with most advanced technology such as FIREHAWK stent, rapamycin‐eluting biodegradable polymer‐coated cobalt‐chromium stent with abluminal groove, was just starting to be applied in 2013. How would these new DESs perform in comparison with imported DESs would be assessed in the future.…”

The Firehawk stent: a review of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent

“…However, the sample size of the TARGET I trial was calibrated to assess a diff erence in LLL, and the event rate was low because of strict angiographic and clinical eligibility criteria, limiting the statistical power of this comparison. TARGET II was a prospective, multicenter, single-arm registry assessing the performance of the Firehawk stent in patients with higher lesion complexity than in the fi rst-inman study and TARGET I trial (Table 2) 14 . A total of 730 patients were enrolled and treated with Firehawk stents in China.…”